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INTRODUCTION
Lymphoplasmacytic sclerosing pan-
creatitis (LPSP)† is a benign form of
chronic pancreatitis characterized clinical-
ly by infrequent attacks of abdominal pain,
jaundice and weight loss, and pathologi-
cally by focal or diffuse chronic or lym-
phoplasmacytic inflammatory infiltrates
centered around pancreatic ducts and duc-
tules, accompanied by obliterative
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Autoimmune pancreatitis is a rare but important cause of pancreatitis that is becoming
increasingly recognized in the West. Lymphoplasmacytic sclerosing pancreatitis (LPSP) is
a benign form of chronic pancreatitis characterized clinically by infrequent attacks of
abdominal pain, jaundice, and weight loss, and pathologically by focal or diffuse chronic or
lymphoplasmacytic inflammatory infiltrates centered around pancreatic ducts and ductules,
accompanied by obliterative phlebitis, acinar atrophy, and interstitial fibrosis. It has been
described alone or as a part of the spectrum of autoimmune gallbladder and biliary tract
disease, with clinical, radiological, and pathological overlap reported with primary scleros-
ing cholangitis. It has been described as “primary sclerosing pancreatitis,” “sclerosing
cholangitis,” “non-alcoholic duct destructive chronic pancreatitis,” and “autoimmune pan-
creatitis.” We report a case of LPSP that mimicked pancreatic adenocarcinoma and was
subsequently treated with a pylorus-preserving Whipple procedure. This may point towards
a primary biliary autoimmune process involving the pancreatic duct, causing a benign form
of chronic pancreatitis that may be difficult to characterize pre-operatively to avoid surgery.
This case typifies the growing awareness of this relatively recently characterized clinical
entity, its similar presentation to pancreatic carcinoma, and the importance for LPSP to be
included in the differential diagnosis of pancreaticobiliary disease. Finally, we review the lit-
erature.phlebitis, acinar atrophy, and interstitial
fibrosis [1-12]. It has been described alone
or as a part of the spectrum of autoimmune
gallbladder and biliary tract disease, with
clinical, radiological, and pathological
overlap reported with primary sclerosing
cholangitis (PSC) [1-9]. LPSP has been
described in the literature as “primary
sclerosing pancreatitis,” “sclerosing
cholangitis,” “non-alcoholic duct destruc-
tive chronic pancreatitis,” and “autoim-
mune pancreatitis” [16]. Lymphoplasma-
cytic sclerosing pancreatitis mimics pan-
creatic adenocarcinoma in clinical presen-
tation with many reported cases in the lit-
erature having undergone pancreaticoduo-
denectomy leading to durable relief of
symptoms and improved quality of life [5-
7, 9-10]. Strict criteria for non-operative
diagnosis of LPSP are currently lacking,
although radiological, serological, and
pathological clues have been suggested [4-
9, 11-13], and a good response to steroid
treatment has been reported to obviate the
need for surgery [14-15]. We report a case
of lymphoplasmacytic sclerosing pancre-
ato-cholangitis, which presented with a
dominant distal common bile duct stric-
ture and a suspicion for pancreatic adeno-
carcinoma, with a negative work-up for
malignancy on imaging and histopatholo-
gy after endoscopy.
CASE REPORT
A77-year-old retired male with a past
medical history significant for diabetes
mellitus well controlled on glipizide, ini-
tially presented to his primary care physi-
cian with intermittent periumbilical pain,
heartburn and a one-year history of 30-
pound weight loss. There was no associa-
tion with food or bowel movements; how-
ever, his symptoms coincided with com-
mencing fluconazole for a fungal infection
of his foot. He denied alcohol use. Initial
evaluation revealed no other etiology to
explain the patient’s symptoms. Ten
months later the patient presented with
painless jaundice and weight loss.
Physical examination at the time revealed
icterus only. On presentation, initial labo-
ratory results revealed a total bilirubin of
11, aspartate transaminase of 246, alanine
transaminase of 422, alkaline phosphatase
of 606, amylase of 309, and lipase of
2,667. The white cell count, hemoglobin,
hematocrit, and electrolytes were normal.
Computerized tomography (CT) scan of
the abdomen revealed slight intrahepatic
ductal dilatation but no masses within the
pancreas. A subsequent abdominal ultra-
sound excluded cholelithiasis. Endoscopic
retrograde cholangio-pancreatography
(ERCP) demonstrated a 2.5 cm distal com-
mon bile duct (CBD) stricture in the supra-
ampullary segment which was stented.
Brushings of the CBD stricture were
benign. The patient was then transferred to
our institution for further management
including endoscopic ultrasound (EUS),
which demonstrated mild narrowing in the
supra-ampullary segment of CBD with
CBD wall thickening measuring 2.1 mm
and an irregular outer border. No pancreat-
ic masses or signs of chronic pancreatitis
were seen. Additionally, no peripancreatic
or celiac axis lymph nodes were seen.
Fine-needle aspiration of bile duct wall
and pancreatic head revealed a few cohe-
sive groups of ductal epithelium with mild
atypia admixed with clusters of benign
glandular epithelium, but no features sug-
gestive of malignancy. A repeat ERCP
showed a tight supra-ampullary CBD
stricture approximately 1.5 cm in length,
without significant proximal CBD and
intrahepatic ductal dilatation. A large bil-
iary sphincterotomy along with brushings
and biopsies of the intrapancreatic portion
of the common bile duct was performed,
followed by placement of a biliary stent.
Repeat CBD brushing and biopsies were
once again negative for malignant cells. At
this point, a long discussion with the
patient and his family took place, explain-
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possible malignancy despite negative
histopathology and cytology so far. 
The patient agreed to undergo surgery
and a successful pylorus-preserving
Whipple procedure was performed (Figure
1). The common bile duct, as well as the
pancreatic duct, revealed areas of periduc-
tal chronic inflammatory infiltrate, reac-
tive epithelial changes, and periductal
fibrosis (Figures 2a, 2b, and 2c). The
fibrosis involved not only the main pan-
creatic duct but its branches as well. The
periductal concentric nature of the fibrosis
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Figure 1. Gross pathology,
showing a mildly dilated pancre-
atic duct without obvious mass
or gross atrophy.
ab
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Figure 2a. Low magnification (x40), showing marked periductal fibrosis (Trichrome stain)
and very mild interstitial fibrosis in the pancreatic parenchyma. Figure 2b. Higher magnifi-
cation (x200), showing a cross section of a duct with periductal fibrosis and lymphoplas-
macytic inflammatory infiltration. Figure 2c. Higher magnification (x200): showing a duct
with lymphoplasmacytic infiltrate around the duct and infiltrating into the epithelium. Figure
2d. Higher magnification (x200), showing a duct displaying squamous metaplasia.was easily evident even on low magnifica-
tion. In many areas, the pancreatic duct
also appeared focally dilated with injury to
the lining epithelium. Squamous metapla-
sia (Figure 2d), mucinous metaplasia, and
papillary hyperplasia in the pancreatic
ductal system were also identified. The
adjacent acini showed evidence of atro-
phy, interstitial fibrosis and relative islet
cell hyperplasia. Calcifications, fat necro-
sis or marked interstitial fibrosis with atro-
phy typical of chronic pancreatitis of other
etiologies (e.g., alcoholic or gall stone
pancreatitis) were not seen. The
histopathologic nature of obstruction to
the common bile duct and pancreatic duct
strongly suggested “sclerosing pancreato-
cholangitis.”
At follow-up, one month after
surgery, the patient was able to tolerate a
regular diet, and had no further episodes of
jaundice or abdominal pain.
DISCUSSION
Sarles and colleagues first described
LPSP in 1961 and suggested the possibili-
ty of immune abnormality in chronic pan-
creatitis as a “phenomenon of self-immu-
nization” [1]. Kawaguchi and colleagues ,
in 1991, reported two cases of LPSP with
cholangitis and considered them to be a
variant of PSC extensively involving pan-
creas, which could clinically mimic pan-
creatic carcinoma [2]. In 1995, Yoshida
and colleagues  described a patient with
chronic pancreatitis who had hyperglobu-
linemia with positive autoantibodies and
responded to steroid therapy — leading to
the notion of chronic pancreatitis caused
by an autoimmune abnormality. More
recently, Nakazawa and colleagues
reported a group of PSC cases with pan-
creatitis, demonstrating a better clinical
course and response to steroids than typi-
cal cases of PSC [4]. The authors conclud-
ed that similar etiologic agents might
impact on both the pancreas and biliary
tract, either simultaneously or in sequence.
LPSP has been also reported to be associ-
ated with Sjogren syndrome, primary bil-
iary cirrhosis, Crohn’s disease, and ulcera-
tive colitis [5, 6].
The histopathologic hallmark of
LPSP is lymphoplasmacytic infiltrates
centered around pancreatic ducts and duc-
tules, accompanied by obliterative
phlebitis, acinar atrophy, and interstitial
fibrosis [1-12]. These lesions typically
cause diffuse or focal swelling with nar-
rowing of main pancreatic duct and/or
common bile duct. LPSP lacks the
parenchymal calcifications, pseudocysts,
and/or fat necrosis commonly found in
other forms of chronic pancreatitis, and a
diagnosis of LPSP can only be made when
the distinctive histologic features are pre-
sent in a patient lacking a history of gall-
stone pancreatitis, pancreas divisum,
excess alcohol ingestion, or other environ-
mental etiology for pancreatic atrophy,
including previous pancreatic radiation
[9]. Pancreata with LPSP often are dif-
fusely enlarged and firm, containing irreg-
ular strictures of the main pancreatic duct
apparent on ERCP [8].
The pathogenesis of LPSP remains
unclear. The inflammatory infiltrates are
largely made up of CD4+ T lymphocytes
with fewer B lymphocytes. It has been
proposed that the T lymphocytes release
cytokines, which in turn up-regulate the
aberrant expression of HLA class II mole-
cules by the duct epithelial cells.
Additionally, antibodies to lactoferrin
(present on ductal acinar cells) and car-
bonic anhydrase II antigens (present on
ductal epithelial cells) may initiate the for-
mation of the lymphocytic infiltrate as a
consequence of the immune reaction
mediated by type 2 helper cells and anti-
bodies [16].
The diagnosis of LPSP is typically
made post-operatively as it mimics pan-
creatic adenocarcinoma, and the majority
of patients often undergo pancreaticoduo-
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suspicion of malignancy. There are no pre-
operative clinical signs of LPSP that help
differentiate it from pancreatic adenocarci-
noma, particularly since both conditions
present with jaundice, weight loss, and/or
nonspecific abdominal pain. The Johns
Hopkins group report [6] no difference in
pre-operative carcinoembryonic antigen
and CA 19.9 (carbohydrate antigen 19.9)
levels between patients with LPSP and
those with pancreatic adenocarcinoma [7].
Although strict criteria for non-operative
diagnosis of LPSP are currently lacking,
some radiologic, serologic and pathologic
clues have been suggested [4-9, 11-13].
Cross-sectional imaging with enhanced
CT or magnetic resonance imaging (MRI)
scans may show diffusely enlarged pan-
creas without a mass [6, 7]. The diffuse
enlargement can also be seen on abdomi-
nal ultrasound, and more accurately by
EUS [7]. A preoperative diagnosis of
LPSP could further be corroborated by
finding of diffuse, irregular narrowing of
the main pancreatic duct on ERCPor mag-
netic resonance cholangio-pancreatogra-
phy [6, 7]. 
Of interest from both a diagnostic
viewpoint and also with regards to medical
management is the association of LPSP
with high serum levels of immunoglobulin
G4 (IgG4) [11, 12] and its response to
treatment with steroids. Hamano and col-
leagues  reported that the elevation in the
level of the IgG4 correlates with the activ-
ity of the disease, and that glucocorticoid
(a daily dose of 0.5 to 1 mg of pred-
nisolone per kilogram of body weight,
tapered to a maintenance dose of 5 to 10
mg per day for six months) therapy
induced clinical remissions and signifi-
cantly decreased serum IgG4 concentra-
tions [11-12, 14-15]. Other laboratory
abnormalities include the presence of anti-
nuclear antibody, anti-lactoferrin antibody,
rheumatoid factor and antibodies to car-
bonic anhydrase II and smooth muscle
[16]. In patients with radiologic and sero-
logic suspicion of LPSP, a negative fine
needle aspiration or biopsy for malignancy
might be further evidence for the benign
nature of the process. However, an ade-
quate sample of tissue is required to evalu-
ate tissue for all pathological features of
LPSP — in most cases a core biopsy will
not provide enough tissue to evaluate these
features [7]. 
Patients may be medically managed
by carefully monitoring response to
steroid therapy in a subset of patients,
obviating the need for surgery.
Nevertheless, the majority of patients with
LPSP will likely continue to be managed
by pancreaticoduodenectomy, based on an
inability to exclude the possibility of pan-
creatic neoplasia, and patients undergoing
this surgery have reported durable relief of
symptoms and improved quality of life [6,
10]. However, progressive disease after
surgery has been reported in up to one-
third of patients, with 25 percent develop-
ing recurrent jaundice and one developing
recurrent pancreatitis in the series of 31
patients reported by the Memorial-Sloan
Kettering group (median length of follow
up was 38 months) [7]. Interestingly, the
Johns Hopkins group reported no patients
with recurrent post-operative jaundice and
only one patient with recurrent pancreati-
tis in their series of 37 patients (median
length of follow up was 33 months) [6]. In
light of the limited clinical experience
with LPSP and variation in post-operative
course, close follow-up is mandatory in all
patients [7].
The clinical, radiologic and patholog-
ic overlap between LPSP and PSC is of
interest in the case we have presented,
since histologic involvement of the com-
mon bile duct by fibrosis, inflammation,
and edema has been demonstrated in 73
percent of patients with LPSP [8]. Hirano
and colleagues also point out that extra-
pancreatic bile duct changes are frequent-
ly associated with autoimmune pancreati-
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inant distal common bile duct stricture,
revealed areas of periductal chronic
inflammatory infiltrate, reactive epithelial
changes, and periductal fibrosis of the
common bile duct, as well as the pancreat-
ic duct. This may point towards a primary
biliary autoimmune process involving the
pancreatic duct, causing a benign form of
chronic pancreatitis which may be difficult
to characterize pre-operatively to avoid
surgery. Furthermore, this case typifies the
growing awareness of this relatively
recently characterized clinical entity, its
similar presentation to pancreatic carcino-
ma, and the importance for LPSP to be
included in the differential diagnosis of
pancreaticobiliary disease. 
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